Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK –positive anaplastic large-cell lymphoma

Christine Damm-Welk, Lara Mussolin, Martin Zimmermann, Marta Pillon, Wolfram Klapper, Ilske Oschlies, Emanuele S. G. d’Amore, Alfred Reiter, Wilhelm Woessmann, Angelo Rosolen

Blood (2014) 123 (3): 334–337.

https://doi.org/10.1182/blood-2013-09-526202

Published: 2014

Includes: Supplemental data

Journal Articles

Phase 1/2 Study Of Brentuximab Vedotin In Pediatric Patients With Relapsed Or Refractory (R/R) Hodgkin Lymphoma (HL) Or Systemic Anaplastic Large-Cell Lymphoma (sALCL): Preliminary Phase 2 Data For Brentuximab Vedotin 1.8 Mg/Kg In The HL Study Arm

Franco Locatelli, MD, Kathleen A Neville, MD, MS, Angelo Rosolen, MD, Judith Landman-Parker, MD, Nathalie Aladjidi, MD, Auke Beishuizen, MD, Stephen Daw, BSc Hons, MBChB, MRCP, Lia Gore, MD, Anna R.K. Franklin, MD, Adedigbo Fasanmade, PhD, Jingyuan Wang, PhD, Jessica Sachs, MD, Christine Mauz-Koerholz, MD

Blood (2013) 122 (21): 4378.

https://doi.org/10.1182/blood.V122.21.4378.4378

Published: 2013

Journal Articles

Early Assessment of Minimal Residual Disease (MRD) by Qualitative PCR for NPM-ALK Identifies Patients At Very High Risk of Relapse in Anaplastic Large Cell Lymphoma

Christine Damm-Welk, PhD, Lara Mussolin, PhD, Marta Pillon, MD, Martin Zimmermann, PhD, Alfred Reiter, MD, Wilhelm Woessmann, MD, Angelo Rosolen, MD

Blood (2011) 118 (21): 1565.

https://doi.org/10.1182/blood.V118.21.1565.1565

Published: 2011

Journal Articles

Limited stage I disease is not necessarily indicative of an excellent prognosis in childhood anaplastic large cell lymphoma

Andishe Attarbaschi, Georg Mann, Angelo Rosolen, Denise Williams, Anne Uyttebroeck, Ildiko Marky, Laurence Lamant, Keizo Horibe, Grazyna Wrobel, Auke Beishuizen, Wilhelm Wössmann, Alfred Reiter, Audrey Mauguen, Marie-Cecile Le Deley, Laurence Brugières, for the European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL) ALCL99 Trial

Blood (2011) 117 (21): 5616–5619.

https://doi.org/10.1182/blood-2010-12-324012

Published: 2011

Journal Articles

MiR-28 Silencing In Germinal Center-Derived Lymphomas

Christof Schneider, MD, Roy L Maute, Pavel Sumazin, PhD, Manisha Brahmachary, PhD, Manu Setty, Laura Pasqualucci, MD, Angelo Rosolen, MD, Christina Leslie, PhD, Katia Basso, PhD, Riccardo Dalla-Favera, MD

Blood (2010) 116 (21): 703.

https://doi.org/10.1182/blood.V116.21.703.703

Published: 2010

Journal Articles

Genomic and Transcriptomic Analyses Revealed Differences and Similarities Between T-Lbl and T-ALL .

Lara Mussolin, Katia Basso, PhD, Antonella Lettieri, Manisha Brahmachary, PhD, Giovanni Cazzaniga, Andrea Califano, PhD, Wei-Keat Lim, Giuseppe Basso, Andrea Biondi, Angelo Rosolen

Blood (2009) 114 (22): 2943.

https://doi.org/10.1182/blood.V114.22.2943.2943

Published: 2009

Journal Articles

Minimal Disseminated Disease Is An Independent Poor Prognosis Marker Among High Risk Burkitt's Lymphoma Patients .

Lara Mussolin, Marta Pillon, Gloria Tridello, Maria Paola Boaro, Emanuele S d'Amore, Luca Lo Nigro, Salvatore Buffardi, Alessandra Lombardi, Alessandra Sala, Claudio Favre, Maurizio Aricò, Angelo Rosolen

Blood (2009) 114 (22): 2944.

https://doi.org/10.1182/blood.V114.22.2944.2944

Published: 2009

Journal Articles

The Impact of the Association of Vinblastine during Induction Chemotherapy and as Maintenance Treatment in Children and Adolescents with High-Risk Anaplastic Large Cell Lymphoma: Results of a Randomized Trial of the EICNHL Group

Marie Cecile Le Deley, Angelo Rosolen, Alfred Reiter, MD, Denise Williams, MD, Keizo Horibe, MD, Grazyna Wrobel, Georg Mann, Jozsef Zsiros, Anne Uyttebroeck, Ildiko Marky, Wolfgang Klapper, Laurence Brugieres

Blood (2008) 112 (11): 577.

https://doi.org/10.1182/blood.V112.11.577.577

Published: 2008

Journal Articles

Investigating Mature B-Cell Lymphomas by MicroRNA Profiling.

Katia Basso, PhD, Pavel Morozov, PhD, Yukiko Kitagawa, MD, Roy L. Maute, Angelo Rosolen, MD, Chang-Zheng Chen, PhD, Andrea Califano, PhD, Riccardo Dalla-Favera, MD

Blood (2007) 110 (11): 3185.

https://doi.org/10.1182/blood.V110.11.3185.3185

Published: 2007

Journal Articles

Anaplastic Large Cell Lymphoma (ALCL) in Children: Equal Efficacy but Greater Toxicity of Chemotherapy Including Methotrexate (MTX) 1g/m 2 in 24 Hour Infusion with Intra-Thecal Injection (IT) Than Chemotherapy with MTX 3g/m 2 in 3 Hours Infusion without IT: Results of the ALCL99-R1 Randomised Trial.

Laurence Brugières, MD, Marie Cécile Le Deley, MD, Angelo Rosolen, MD, Denise Williams, MD, Ke Horibe, MD, Grazyna Wrobel, MD, Anne Uyttebroeck, MD, Auke Beishuizen, MD, Georg Mann, MD, Karin Mellgren, MD, Alfred Reiter, MD

Blood (2006) 108 (11): 398.

https://doi.org/10.1182/blood.V108.11.398.398

Published: 2006

Journal Articles

Identification of Normal and Neoplastic Human Mature B Cells “miRome”.

Katia Basso, PhD, Pavel Morozov, PhD, Andrea Califano, PhD, Angelo Rosolen, MD, Jacqueline Chau, Chang-Zheng Chen, PhD, Riccardo Dalla-Favera, MD

Blood (2006) 108 (11): 2239.

https://doi.org/10.1182/blood.V108.11.2239.2239

Published: 2006

NARROW

Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK –positive anaplastic large-cell lymphoma

Phase 1/2 Study Of Brentuximab Vedotin In Pediatric Patients With Relapsed Or Refractory (R/R) Hodgkin Lymphoma (HL) Or Systemic Anaplastic Large-Cell Lymphoma (sALCL): Preliminary Phase 2 Data For Brentuximab Vedotin 1.8 Mg/Kg In The HL Study Arm

Early Assessment of Minimal Residual Disease (MRD) by Qualitative PCR for NPM-ALK Identifies Patients At Very High Risk of Relapse in Anaplastic Large Cell Lymphoma

Limited stage I disease is not necessarily indicative of an excellent prognosis in childhood anaplastic large cell lymphoma

MiR-28 Silencing In Germinal Center-Derived Lymphomas

Genomic and Transcriptomic Analyses Revealed Differences and Similarities Between T-Lbl and T-ALL .

Minimal Disseminated Disease Is An Independent Poor Prognosis Marker Among High Risk Burkitt's Lymphoma Patients .

The Impact of the Association of Vinblastine during Induction Chemotherapy and as Maintenance Treatment in Children and Adolescents with High-Risk Anaplastic Large Cell Lymphoma: Results of a Randomized Trial of the EICNHL Group

Investigating Mature B-Cell Lymphomas by MicroRNA Profiling.

Anaplastic Large Cell Lymphoma (ALCL) in Children: Equal Efficacy but Greater Toxicity of Chemotherapy Including Methotrexate (MTX) 1g/m 2 in 24 Hour Infusion with Intra-Thecal Injection (IT) Than Chemotherapy with MTX 3g/m 2 in 3 Hours Infusion without IT: Results of the ALCL99-R1 Randomised Trial.

Identification of Normal and Neoplastic Human Mature B Cells “miRome”.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only